REG - Renalytix PLC - Appointment of Joint Corporate Broker

RenalytixAnnouncement

21/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240821:nRSU1687Ba&default-theme=true

RNS Number : 1687B  Renalytix PLC  21 August 2024

Renalytix plc

("Renalytix" or the "Company")

 

Appointment of Joint Corporate Broker

 

LONDON and NEW YORK, 21 August 2024 - Renalytix plc (NASDAQ: RNLX) (LSE:
RENX), an artificial intelligence-enabled in vitro diagnostics company,
focused on optimizing clinical management of kidney disease to drive improved
patient outcomes and advance value-based care, announces the appointment of
Oberon Capital (a trading name of Oberon Investments Limited) as Joint
Corporate Broker with immediate effect.

 

 

For further information, please contact:

 

 Renalytix plc                                www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                        Via Walbrook PR

 Stifel (Nominated Adviser and Joint Broker)  Tel: 020 7710 7600
 Nicholas Moore / Nick Harland / Ben Good

 Oberon Capital (Joint Broker)                Tel: 020 3179 5300
 Mike Seabrook / Nick Lovering

 Investec Bank plc (Joint Broker)             Tel: 020 7597 4000
 Gary Clarence / Shalin Bhamra

 Walbrook PR Limited                          Tel: 020 7933 8780 or renalytix@walbrookpr.com
                                              (http://renalytix@walbrookpr.com)
 Alice Woodings / Charlotte Edgar             Mob: 07407 804 654 / 07884 664 686

 CapComm Partners
 Peter DeNardo                                Tel: 415-389-6400 or investors@renalytix.com (http://investors@renalytix.com)

 

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory
services company that is the global founder and leader in the new field of
bioprognosis™ for kidney health. The leadership team, with a combined 200+
years of healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment for rapid
progressive decline in kidney function in adult patients with T2D and early
CKD (stages 1-3). We believe that by understanding how disease will progress,
patients and providers can take action early to improve outcomes and reduce
overall health system costs. For more information, visit www.renalytix.com
(https://www.globenewswire.com/Tracker?data=ThoNM1PDWeVIxIN1XNvxXoh0EK3Og6d0k06ZfN9GrAjS1_QubydWs_nD7MTPteCUCpzWMT-T9VtSxqrwDhSDHeCPMgeDBf4ZA-6KeA6aJT4=)
.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPPMMLTMTMTBTI